Synergistic Cisplatin/Doxorubicin Combination Chemotherapy for Multidrug-Resistant Cancer via Polymeric Nanogels Targeting Delivery.
Haiqiu WuHaojie JinCun WangZihao ZhangHaoyu RuanLuyan SunChen YangYongjing LiWenxin QinChangchun WangPublished in: ACS applied materials & interfaces (2017)
Combination chemotherapy has been proposed to achieve synergistic effect and minimize drug dose for cancer treatment in clinic application. In this article, the stimuli-responsive polymeric nanogels (<100 nm in size) based on poly(acrylic acid) were designed as codelivery system for doxorubicin and cisplatin to overcome drug resistance. By chelation, electrostatic interaction, and π-π stacking interactions, the nanogels could encapsulate doxorubicin and cisplatin with designed ratio and high capacity. Compared with free drugs, the nanogels could deliver more drugs into MCF-7/ADR cells. Significant accumulation in tumor tissues was observed in the biodistribution experiments. The in vitro antitumor studies demonstrated the superior cell-killing activity of the nanogel drug delivery system with a combination index of 0.84, which indicated the great synergistic effect. All the antitumor experimental data revealed that the combination therapy was effective for the multidrug-resistant MCF-7/ADR tumor with reduced side effects.
Keyphrases
- cancer therapy
- multidrug resistant
- drug delivery
- combination therapy
- adverse drug
- drug resistant
- single cell
- gram negative
- acinetobacter baumannii
- breast cancer cells
- locally advanced
- induced apoptosis
- cell cycle arrest
- electronic health record
- drug release
- gene expression
- primary care
- papillary thyroid
- drug induced
- klebsiella pneumoniae
- cystic fibrosis
- emergency department
- signaling pathway
- cell therapy
- computed tomography
- escherichia coli
- oxidative stress
- cell proliferation
- young adults
- mesenchymal stem cells
- cell death
- childhood cancer